MS

2 Pharma Buyout Targets That May Surprise You
Motley Fool
Tue, 06/27/17 - 09:46 am
Biogen
Bristol-Myers Squibb
M&A
MS
multiple sclerosis
immuno-oncology
Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms
Fierce Pharma
Sat, 06/24/17 - 09:14 am
Roche
Ocrevus
MS
multiple sclerosis
Mylan's Copaxone copy could face another hold-up with FDA info request
Fierce Pharma
Fri, 06/16/17 - 09:56 pm
Mylan
Copaxone
FDA
generics
Teva Pharmaceutical
MS
multiple sclerosis
Roche looks into PML report for Ocrevus patient
BioPharma Dive
Thu, 05/25/17 - 11:25 am
Roche
PML
Ocrevus
Genentech
MS
multiple sclerosis
Celgene touts ozanimod MS data, but disability benefit weak over rival med
Fierce Biotech
Mon, 05/22/17 - 09:41 am
Celgene
ozanimod
MS
multiple sclerosis
Biogen
Avonex
Teva crashes out of laquinimod MS program
BioPharma Dive
Tue, 05/9/17 - 10:17 am
Teva Pharmaceutial
MS
multiple sclerosis
laquinimod
Troubled Teva’s successor to Copaxone just failed a big PhIII test for multiple sclerosis
Endpoints
Sun, 05/7/17 - 11:11 am
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
laquinimod
Active Biotech
Celgene highlights MS drug in diversification push
BioPharma Dive
Thu, 04/27/17 - 05:47 pm
Celgene
MS
multiple sclerosis
ozanimod
Biogen looks to M&A to overcome competition to its MS franchise
Fierce Pharma
Mon, 04/24/17 - 10:05 pm
Biogen
M&A
MS
Novartis' Gilenya patent loss sets MS market up for battle with early generics
Fierce Pharma
Thu, 04/13/17 - 06:49 pm
Novartis
Gilenya
MS
multiple sclerosis
generics
4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't
Motley Fool
Wed, 04/12/17 - 10:33 am
Roche
Tecentriq
Perjeta
HER-2 postive breast cancer
Ocrevus
MS
multiple sclerosis
diagnostics
generics
biosimilars
Why Roche's New Drug Is Bad News For Biogen
Barron's
Sun, 04/9/17 - 12:20 pm
Roche
Biogen
Ocrevus
multiple sclerosis
MS
Tysabri
Tecfidera
Patent decision puts 95% of Acorda revenue at risk
BioPharma Dive
Tue, 04/4/17 - 07:23 pm
Acorda Therapeutics
patents
AMPYRA
multiple sclerosis
MS
Teva Receives Positive Outcome for COPAXONE® 40 mg/ml 3 Times Weekly Label in Europe
Yahoo
Mon, 04/3/17 - 09:14 am
Teva
Copaxone
Europe
MS
multiple sclerosis
Forward Pharma Intends to Appeal Decision in Patent Interference Proceeding with Biogen Inc.
Yahoo
Sat, 04/1/17 - 08:07 am
Biogen
Tecfidera
patents
Forward Pharma
MS
multiple sclerosis
Roche secures FDA approval for Ocrevus for two types of MS
BioPharma Dive
Tue, 03/28/17 - 11:56 pm
Roche
Ocrevus
FDA
ocrelizumab
MS
multiple sclerosis
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency
Yahoo/Reuters
Thu, 03/23/17 - 09:32 am
Sanofi
Roche
GSK
FDA
Ocrevus
MS
Dupixent
eczema
generics
Advair
Mylan Labs
Sanofi to be a leader in MS, but not yet
BioPharma Dive
Wed, 03/22/17 - 10:35 pm
Sanofi
MS
multiple sclerosis
Lemtrada
Aubagio
Biogen Wins Tecfidera Patent Case
Investopedia
Wed, 03/22/17 - 10:02 am
Biogen
Tecfidera
patents
Kyle Bass
MS
multiple sclerosis
Ozanimod Safety Still A Question Mark For Celgene
Seeking Alpha
Thu, 02/23/17 - 09:13 am
Celgene
ozanimod
MS
multiple sclerosis

Pages